Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...
The 9-0 decision, authored by Justice Ketanji Brown Jackson, overturned a previous lower appellate court ruling that had ...
RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...
On Sunday, Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented data on pancreatic cancer that is moving the field ...
FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...
The results of the survey revealed that the growing direct-to-patient approach is having a significant impact on how ...
Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating ...
A wave of expiries will hit high-value assets, including Keytruda, Eliquis, Ibrance, and Trulicity, amplifying revenue ...
A trio of deals from Eli Lilly, Servier, and Avenzo highlights continued industry investment in rare diseases and oncology, ...
Learn how increasing healthcare complexity and specialty medication adoption are reshaping patient access and affordability ...
FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major ...
Pfizer will embed a Chai platform instance trained on proprietary datasets, signaling deeper operational integration than typical external AI service usage and potentially accelerating biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results